peptideResearch chemicalMarketed in Japan (as GHRP-2, brand name GHRP) as a diagnostic agent for GH deficiency testing, not approved in the US
PralmorelinBenefits, Dosage & Interactions
Also known as: GHRP-2 acetate
Pralmorelin, also known by its research name GHRP-2 acetate, is a synthetic peptide belonging to the growth hormone-releasing peptide (GHRP) family. It was developed to stimulate the secretion of growth hormone (GH) from the pituitary gland. Research on Pralmorelin focuses on bone and joint health and tissue recovery.
How much Pralmorelin do people take?
1 mcg/kg administered as a single intravenous bolus in the GH-releasing peptide-2 diagnostic test studies. Route reported: Intravenous bolus, used only as a diagnostic stimulation agent in these studies. Frequency reported: Single administration for the diagnostic test. These are amounts documented in the cited studies and labels for Pralmorelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
How is pralmorelin different from injected growth hormone?
Pralmorelin, also called GHRP-2, stimulates growth hormone release through the ghrelin receptor. Somatropin supplies growth hormone directly. A stimulation-test response does not establish that repeated use improves strength, recovery, or healthy aging.
Source: Human growth hormone secretagogue research
Browse compound evidence cardsPlasma half-life
0.42–0.69 h
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Pralmorelin in the cited sources. Published ranges are not dosing advice.
Mixing Pralmorelin: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, Pralmorelin vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the Pralmorelin entry is written from. Each number matches an inline marker above.
- [1]A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiencyChihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y, KP-102 Study Group · European Journal of Endocrinology · 2007 · Peer-reviewed · PMID 17609397
- [2]Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary DisorderSuzuki S, Ruike Y, Ishiwata K, Naito K, Igarashi K, Ishida A, Fujimoto M, Koide H, Horiguchi K, Tatsuno I, Yokote K · Journal of the Endocrine Society · 2022 · Peer-reviewed · PMID 35795807
- [3]Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LNDrugs in R&D · 2004 · Peer-reviewed · PMID 15230633
References & Evidence
Sources on this page that document Pralmorelin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Pralmorelin studied for?
What is Pralmorelin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Pralmorelin, also known by its research name GHRP-2 acetate, is a synthetic peptide belonging to the growth hormone-releasing peptide (GHRP) family. It was developed to stimulate the secretion of growth hormone (GH) from the pituitary gland. Unlike growth hormone-releasing hormone (GHRH), which acts on specific GHRH receptors, pralmorelin exerts its effects by binding to ghrelin/growth hormone secretagogue receptors (GHSRs). These receptors are found in various tissues throughout the body, including the pituitary gland and the hypothalamus. The stimulation of these receptors leads to a pulsatile release of growth hormone. Pralmorelin is not a controlled substance and has been studied for various potential applications due to its potent GH-releasing capabilities. It is typically administered via injection.
The development of GHRPs like pralmorelin aimed to identify compounds that could act independently of, or synergistically with, endogenous GHRH to enhance GH secretion, offering potential therapeutic avenues for conditions characterized by GH deficiency or catabolic states (PubChem, DrugBank).
What does the research say about Pralmorelin?
Tap a section to expand.
Pralmorelin functions as a synthetic agonist of the growth hormone secretagogue receptor (GHSR), commonly known as the ghrelin receptor. When pralmorelin binds to GHSRs, particularly those located on somatotroph cells in the anterior pituitary gland, it triggers a cascade of intracellular events that culminate in the release of stored growth hormone. This mechanism is distinct from that of growth hormone-releasing hormone (GHRH), which binds to its own specific receptors. However, pralmorelin's GH-releasing activity is often synergistic with GHRH; GHRH primes the somatotrophs, making them more responsive to stimulation by GHRPs. This synergy means that the combined effect of GHRP-2 and GHRH on GH release is greater than the sum of their individual effects (DrugBank, PubMed research).
Beyond direct pituitary stimulation, GHSRs are also found in the hypothalamus, where pralmorelin may influence the release of GHRH and inhibit somatostatin, a natural suppressor of GH secretion. By reducing somatostatin's inhibitory tone, pralmorelin further enhances the overall pulsatile release of growth hormone. The primary effect is an increase in the amplitude and frequency of GH pulses, rather than a sustained elevation. This pulsatile release pattern aims to mimic the body's natural GH secretion (Examine.com, NIH ODS).
Source for this section: Sources for How does Pralmorelin work?: Jumps to this entry in the sources and references list at the end of the page.
Studies on pralmorelin, or GHRP-2, have explored its potential for stimulating growth hormone release, which indirectly suggests potential benefits associated with growth hormone's known physiological roles. These potential benefits are largely extrapolated from general growth hormone effects and early research, and are not definitively established for pralmorelin itself.
* **Muscle Growth and Body Composition:** Increased growth hormone levels are associated with anabolism, protein synthesis, and potentially fat metabolism. Research suggests that elevated GH levels can contribute to improvements in lean body mass and a reduction in adipose tissue. In animal models and limited human studies, GHRPs have been shown to influence body composition by promoting muscle accretion and reducing fat mass, likely through their influence on GH and IGF-1 levels (Cochrane reviews, PubMed clinical trials).
* **Bone Density:** Growth hormone plays a crucial role in bone metabolism and density. In conditions like GH deficiency, compromised bone health is a concern. By stimulating GH release, pralmorelin may indirectly support bone mineral density by promoting osteoblastic activity and the formation of new bone tissue (NIH ODS, Endocrine Society research).
* **Recovery and Tissue Repair:** Growth hormone and its downstream mediator, insulin-like growth factor 1 (IGF-1), are involved in tissue repair and regeneration. Enhanced GH secretion may aid in accelerated recovery from injury, improve wound healing, and support the maintenance of connective tissues (Mayo Clinic research, MedlinePlus).
* **Anti-aging Effects:** Given that natural growth hormone production declines with age, there is interest in compounds that can safely restore GH levels. While not a direct anti-aging agent, the potential improvements in body composition, bone density, and skin elasticity associated with higher GH levels are sometimes considered in the context of healthy aging (Examine.com, PubChem).
Evidence for pralmorelin's effects primarily stems from preclinical studies and early-phase human clinical trials focusing on its ability to stimulate growth hormone release. Its potent GH-releasing activity has been consistently demonstrated in various research settings.
In animal models, pralmorelin has been shown to dose-dependently increase plasma growth hormone concentrations. For example, studies in rats and dogs demonstrated significant increases in GH levels following administration, supporting its role as a robust GH secretagogue (DrugBank, PubMed research).
Human clinical trials, often involving healthy volunteers or individuals with GH deficiency, have confirmed that pralmorelin effectively stimulates GH secretion. These studies typically observe a rapid and pulsatile increase in GH levels, peaking within 30-60 minutes post-administration. The GH-releasing effect is generally more pronounced when administered in synergy with GHRH, indicating a complementary mechanism of action (Examine.com, NIH ODS research).
While the primary evidence confirms its GH-releasing properties, direct evidence for long-term health benefits, such as specific improvements in muscle mass, bone density, or anti-aging effects in healthy populations using pralmorelin, is less robust and often relies on extrapolation from the known effects of growth hormone itself. Research has explored its potential diagnostic utility for growth hormone deficiency but its therapeutic application for other indications is still investigational and not widely established (MedlinePlus, Cochrane reviews).
Commonly reported side effects associated with pralmorelin (GHRP-2) and other GHRPs are generally related to their effects on growth hormone and other hormonal systems. These include:
* **Increased Hunger:** Pralmorelin acts on ghrelin receptors, and ghrelin is known as a 'hunger hormone.' Therefore, increased appetite and hunger are frequently reported side effects.
* **Water Retention:** Some individuals may experience mild fluid retention, leading to temporary weight gain or puffiness.
* **Tingling or Numbness:** Sensations of tingling or numbness, particularly in the extremities, can occur, which is a known side effect associated with elevated growth hormone levels.
* **Headache:** Headaches have been reported by some users.
* **Dizziness:** Mild dizziness can occur.
* **Fatigue:** Some individuals may experience a temporary feeling of fatigue or lethargy after administration.
* **Injection Site Reactions:** As an injectable, local reactions such as redness, itching, pain, or swelling at the injection site are possible.
More significant side effects are less common but can include temporary increases in prolactin and cortisol levels, which are generally not considered clinically significant with short-term use but warrant consideration. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pralmorelin should be used with caution, and certain considerations should be taken into account. Individuals with pre-existing medical conditions, particularly those affecting the endocrine system, cardiovascular system, or glucose metabolism, should consult a healthcare professional before considering its use. Its impact on insulin sensitivity and glucose levels may be a concern for individuals with diabetes or pre-diabetes, as growth hormone can affect glucose regulation. Long-term safety data for pralmorelin in healthy individuals is limited, and its effects beyond short-term GH release are not fully established. Pregnant or breastfeeding individuals should avoid use due to insufficient safety data. Children and adolescents should not use pralmorelin unless specifically directed and supervised by a pediatric endocrinologist for a diagnosed condition, as it can influence growth and development. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pralmorelin is contraindicated in individuals with known hypersensitivity to the compound or any of its excipients. It should not be used in individuals with active cancer or a history of certain hormone-sensitive cancers, as growth hormone can influence cell proliferation. Individuals with uncontrolled diabetes mellitus or severe cardiovascular disease should avoid its use. Certain pituitary or hypothalamic disorders where increased GH secretion could be detrimental would also represent contraindications. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While pralmorelin's primary interaction is with GHSRs, its effects on growth hormone release can be influenced by other substances. Concomitant use with somatostatin or somatostatin analogs may reduce its efficacy, as somatostatin inhibits GH secretion. Similarly, high doses of corticosteroids can suppress growth hormone release and might counteract some of pralmorelin's effects. Substances that significantly alter glucose metabolism should be used with caution, as pralmorelin can influence insulin sensitivity. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pralmorelin, or GHRP-2, has a half-life of approximately 1 hour, meaning it is rapidly cleared from the body. Due to its short half-life, multiple daily administrations might be considered to sustain elevated growth hormone levels, if clinically appropriate. Its effects are generally observed shortly after administration, with peak growth hormone levels occurring within 30-60 minutes. It can be taken either with or without food. However, taking it on an empty stomach might lead to a slightly more pronounced GH pulse due to less interference from post-meal nutrient responses, though this is not always a strict requirement. Individual needs vary — talk to a licensed clinician. Dose is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Pralmorelin?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Pralmorelin is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Pralmorelin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Pralmorelin
Pralmorelin, also known as GHRP-2, is a synthetic peptide that stimulates the release of growth hormone from the pituitary gland by activating specific receptors. It's distinct from growth hormone-releasing hormone (GHRH).
Pralmorelin primarily works by binding to growth hormone secretagogue receptors (GHSRs) in the pituitary gland and hypothalamus. This binding triggers the release of stored growth hormone in a pulsatile manner, mimicking natural GH secretion.
Common side effects can include increased hunger, temporary water retention, tingling sensations, headache, dizziness, fatigue, and injection site reactions. These are generally mild and temporary.
Pralmorelin's crucial to consult a healthcare professional before combining pralmorelin with any other medications or supplements. Substances like somatostatin analogs, corticosteroids, or compounds affecting glucose metabolism might interact with its effects.
No, pralmorelin is not growth hormone itself. Instead, it is a peptide that *stimulates* your body's own pituitary gland to release its natural growth hormone. This results in a pulsatile release rather than a constant, exogenous supply of GH.
As a peptide, Pralmorelin can overlap with other supplements, prescription medicines, hormones and peptides. With a reported plasma half-life near 0.42 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Pralmorelin with no sign-up.
Pralmorelin is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 0.42 hours, which is what drives how often it is redosed. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Pralmorelin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Pralmorelin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 0.42 hours is why protocols often split Pralmorelin across the day rather than using a single dose. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Pralmorelin clears quickly (plasma half-life around 0.42 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Pralmorelin the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Pralmorelin, also called GHRP-2, stimulates growth hormone release through the ghrelin receptor. Somatropin supplies growth hormone directly. A stimulation-test response does not establish that repeated use improves strength, recovery, or healthy aging.
No. Hormone release is a biological measurement, not a patient-centered outcome. Diagnostic testing, treatment of a documented deficiency, and use for bodybuilding are different questions and need different supporting evidence.
1 mcg/kg administered as a single intravenous bolus in the GH-releasing peptide-2 diagnostic test studies. Route reported: Intravenous bolus, used only as a diagnostic stimulation agent in these studies. Frequency reported: Single administration for the diagnostic test. These are amounts documented in the cited studies and labels for Pralmorelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Pralmorelin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN(opens PubMed in a new tab)Drugs R D · 2004 · PMID 15230633 · https://pubmed.ncbi.nlm.nih.gov/15230633/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 9940988(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9940988
Verify at
Publisher search links for Pralmorelin. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Pralmorelin?
Plain-text summary, safe to quote verbatim:
Pralmorelin, also known by its research name GHRP-2 acetate, is a synthetic peptide belonging to the growth hormone-releasing peptide (GHRP) family. It was developed to stimulate the secretion of growth hormone (GH) from the pituitary gland. Research on Pralmorelin focuses on bone and joint health and tissue recovery.
Source: DoseRoutine — https://doseroutine.com/library/pralmorelin
Pralmorelin cheat sheet
DoseRoutine cheat sheet · Peptide
Pralmorelin
Pralmorelin, also known by its research name GHRP-2 acetate, is a synthetic peptide belonging to the growth hormone-releasing peptide (GHRP) family. It was developed to stimulate the secretion of growth hormone (GH) from the pituitary gland.
Evidence
Limited
Human observational or case data only — no randomized trials.
Studied range
1 mcg/kg administered as a single intravenous bolus in the GH-releasing peptide-2 diagnostic test studies
Route
Intravenous bolus, used only as a diagnostic stimulation agent in these studies
Frequency studied
Single administration for the diagnostic test
Half-life
0.42–0.69 h
Storage
Not reported in these clinical sources
Research chemicalMarketed in Japan (as GHRP-2, brand name GHRP) as a diagnostic agent for GH deficiency testing, not approved in the USBone JointRecovery
Key references
- A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007)
- Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder (2022)
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN (2004)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/pralmorelin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Pralmorelin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/pralmorelin
What compounds are similar to Pralmorelin?
Others in the peptide category or studied for the same goals.
Which goals is Pralmorelin used for?
Other compounds studied for the same benefits as Pralmorelin.
Bone & Joint Health
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.